Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer

Editor’s Choice: Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer

Editorial: From one-size-fits all to biology-driven care: Emerging paradigms in gynecologic oncology

Hosted by:
Paola Gehrig, MD, Associate Editor of Gynecologic Oncology

Featuring:
Bradley Corr, University of Colorado, Aurora, CO, USA
Ursula Matulonis, Dana-Farber Cancer Institute, Boston, MA, USA
Mary M. Mullen, Washington University School of Medicine, St Louis, MO, USA
Rebecca Arhend, University of Alabama at Birmingham, Birmingham, AL, USA

Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net